A 68% reduction in relapse risk is the number that earned Enspryng its second FDA fast-track designation. The agency granted Priority Review to Roche’s supplemental BLA for satralizumab in MOGAD after the Phase III METEOROID trial hit its primary endpoint: time to first relapse was significantly longer on satralizumab than on placebo (p=0.0025) in adults and adolescents with myelin oligodendrocyte glycoprotein antibody-associated disease. That result is the clinical foundation for the entire filing.
The strategic context matters here. Satralizumab already carries FDA approval for AQP4-positive NMOSD, granted in August 2020, so this is an expansion into a related but distinct neuroimmune condition rather than a first-in-class entry. MOGAD and NMOSD share some clinical overlap but differ in antibody target and, critically, in how well existing therapies translate between them. Approved options for MOGAD remain limited, and the disease has largely been managed off-label, making a positive pivotal dataset meaningful for the trial community regardless of how the FDA ultimately rules.
MOGAD’s prevalence runs roughly 3 to 4 per 100,000 people in U.S. population studies, which puts the addressable patient population in a range typical for rare neurological indications. That size is enough to support a Priority Review designation, which the FDA awards when a drug may offer a substantial improvement over available therapy, but it also means enrollment for any confirmatory or post-approval trial will require careful site selection. The METEOROID design, measuring time to first relapse across a double-blind treatment period, gives regulators a clean endpoint to evaluate, and the p-value leaves little statistical ambiguity.
Priority Review sets a six-month FDA review clock rather than the standard ten months, so a decision is likely in the first half of 2027. The number to track between now and then is whether the agency requests any additional safety data on satralizumab's IL-6 receptor blockade mechanism in the MOGAD-specific population, which skews younger and includes adolescents in a way the NMOSD approval did not require at launch.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
